Sign in

    Raymond Wu

    Research Analyst at Ladenburg Thalmann

    Raymond Wu is a Research Analyst at Ladenburg Thalmann, specializing in healthcare equity research with active coverage of clinical-stage biotechnology companies such as Eledon Pharmaceuticals and Eyenovia. His analyst activity includes participation in earnings calls and formulation of research questions for phase trial data, with a performance record that includes published questions and analysis but no independently published ranking or return metrics on major platforms. Wu has held his analyst position at Ladenburg Thalmann since at least 2023, following a tenure focused on basic materials and event-driven strategies at prior firms, although specific earlier employers are not disclosed in public sources. He holds applicable industry credentials, including FINRA registration, and often collaborates with senior analysts in his division.

    Raymond Wu's questions to Eledon Pharmaceuticals (ELDN) leadership

    Raymond Wu's questions to Eledon Pharmaceuticals (ELDN) leadership • Q1 2023

    Question

    Raymond Wu, on behalf of Matt Kaplan at Ladenburg Thalmann, asked about the response from doctors and patients to the initial renal transplantation data and whether it is building awareness for the Phase 2 trial. He also questioned how the magnitude of eGFR benefit in the BESTOW trial might influence the future clinical and regulatory path.

    Answer

    President and Chief Scientific Officer Steve Perrin described the physician receptivity as "absolutely amazing," noting excitement in the field to reengage the CD40 ligand pathway. CEO David-Alexandre Gros explained that the BESTOW trial is a superiority study, and even a small, statistically significant delta in eGFR would be clinically meaningful, as lower eGFR is exponentially correlated with increased hospitalization and graft failure risk. Perrin added that even small eGFR differences can significantly impact long-term graft survival.

    Ask Fintool Equity Research AI